BioMarin Pharmaceuticals
BMRN
394 hedge funds and large institutions have $16.8B invested in BioMarin Pharmaceuticals in 2015 Q3 according to their latest regulatory filings, with 55 funds opening new positions, 149 increasing their positions, 139 reducing their positions, and 51 closing their positions.
8% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 51
7% more repeat investments, than reductions
Existing positions increased: 149 | Existing positions reduced: 139
1% more funds holding
Funds holding: 392 → 394 (+2)
7% less call options, than puts
Call options by funds: $211M | Put options by funds: $228M
13% less funds holding in top 10
Funds holding in top 10: 16 → 14 (-2)
22% less capital invested
Capital invested by funds: $21.7B → $16.8B (-$4.84B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$365M |
| 2 |
JP Morgan Chase
New York
|
+$326M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$177M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
+$64.9M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$58.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair & Company
Chicago,
Illinois
|
-$143M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
-$93.2M |
| 3 |
Primecap Management
Pasadena,
California
|
-$83.8M |
| 4 |
BRC
Blue Ridge Capital
New York
|
-$77.5M |
| 5 |
Jennison Associates
New York
|
-$73M |
BMRN Hedge Fund Activity: Q3 2015 in Review
394 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q3 2015, worth a combined $16.8B — down 22% from $21.7B a quarter earlier.
Buyers outnumbered sellers: 55 funds opened new BMRN positions and 51 closed out — a net gain of 4 holders — while 149 added to existing stakes and 139 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $365M. The largest seller was William Blair & Company, cutting an estimated $143M.
- 394 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q3 2015, up from 392 in Q2 2015.
- Funds reported $16.8B of BioMarin Pharmaceuticals stock for Q3 2015, down 22% quarter-over-quarter.
- 55 funds opened new BioMarin Pharmaceuticals positions in Q3 2015 and 51 closed out, a net change of +4 holders.
- The largest BioMarin Pharmaceuticals buyer in Q3 2015 was Fidelity Investments, an estimated $365M added.
- The largest BioMarin Pharmaceuticals seller in Q3 2015 was William Blair & Company, an estimated $143M sold.
Based on aggregated 13F filings for Q3 2015.